Ingredients

The authors present analysis of the state of control of intermediate identity and quality, based on analysis of recently submitted DMFs.

Asking the right questions is crucial to establishing a biopharmaceutical facility design.

Gauging the adequate level and type of screening is the challenge when identifying relevant crystalline forms.

Hazardous reagents can prove to be faster, simpler, cheaper, and greener.

ICIG’s CordenPharma Group expands fermentation-based production technology with acquisition of Sandoz Site.

Scale-down modeling is instrumental in supporting the development of downstream biopharma manufacturing processes.

Hazardous reagents can simplify processes and provide higher yields and purities.

The chemical distribution industry has formed an international chemical trade association to address global issues.

Sustainable harvesting combined with CMO expertise helped Centroflora CMS ensure supply continuity after it acquired Boehringer Ingelheim's non-captive API phytochemicals portfolio.

Time and sensitivity are essential for analytical technologies in all phases of biopharma development.

Novasep is building a new synthesis laboratory and adding capacity for kilogram-scale batches of synthetic molecules that are needed for biological testing and preclinical trials, at its Pennsylvania, US facility.

Planned expansion at Onyx Scientific add laboratories, GMP suites, and storage space.

Andrew Badrot, founder and CEO of Centroflora CMS, discussed the acquisition and technical transfer of Boehringer Ingelheim’s (BI) non-captive phytochemical API portfolio with Pharmaceutical Technology.

FDA issued a warning letter to Zhejiang Hisun Pharmaceutical Co., Ltd., as a result of inspections that took place on March 2–7, 2015 at the Taizhou City, Zhejiang Province, API manufacturing facility.

Nanoscale catalysts and engineered nanoparticles may have a big impact on small-molecule pharmaceuticals.

FDA approved 45 novel new drugs in 2015, the highest number of approvals since 1996 and second-highest ever.

BASF and Sumitomo Chemical explore in vitro system for chemical safety evaluation.

Capsugel adds clinical trial and commercial manufacturing, as well as particle engineering services with two acquisitions.

A strong API market is expected in 2016 despite fewer new drug approvals.

The ReactoMate Datum controlled lab reactor system accommodates a range of vessel sizes.

Multi-component coupling reactions for the generation of heterocycles in fewer steps reduced processing times, cost, and waste are attracting interest.

Ash Stevens has received FDA’s approval to manufacture Takeda’s multiple myeloma drug, ixazomib, at its facility in Riverview, Michigan.

BASF’s new multi-product amines plant in Ludwigshafen, Germany meets growing demand for amines in various applications, including pharmaceuticals.

Efficient syntheses are possible using multi-component and cross-dehydrogenative, heteroaromatic C–H silylation reactions

The Transform hydrate-able film from Lubrizol LifeSciences is compatible with a range of APIs.